文献速递肿瘤 PET/CT放射性药物与辐射防护

临床前研究聚焦当代放射性标记化合物用于PET感染显像的靶向机制

Preclinical Research Highlighting Contemporary Targeting Mechanisms of Radiolabelled Compounds for PET Based Infection Imaging.
PubMed 文献 · Semin Nucl Med · 2023-04-02

该综述梳理感染临床前PET显像放射性药物的研发现状,涵盖离子型PET核素、小分子、肽类、免疫PET及未来技术,并提出理想感染显像剂为PET联合CT、更理想为MRI,强调标准化临床前评价可促进临床转化。

要点

  • 感染显像放射性药物靶点涵盖细胞壁合成、麦芽糊精转运、铁载体、叶酸合成及蛋白合成。
  • 已报道用于细菌、真菌、病毒及分枝杆菌感染的多种小分子、肽类与免疫PET显像剂。
  • 作者提出理想感染显像剂为PET联合CT、更理想为MRI,标准化临床前评价可促进转化。

核心结论

  • 作者提出理想感染显像剂为PET联合CT、更理想为MRI。
  • 标准化与优化放射性药物临床前评价可促进临床转化并减少在欠佳候选物上花费的时间。

研究设计与样本

  • 该文为综述,检索并汇总感染临床前显像领域的放射性药物研发进展。

主要发现

  • 评估了64CuCl2与68GaCl2等PET放射性核素离子型制剂用于细菌感染显像。
  • 小分子放射性药物靶点以细胞壁合成、麦芽糊精转运(如[18F]F-麦芽三糖)、铁载体(细菌与真菌感染)、叶酸合成途径(如[18F]F-PABA)及蛋白合成(放射性标记嘌呤霉素)为主。
  • 分枝杆菌特异性抗生素、抗真菌药与抗病毒药也被研究作为感染显像剂。
  • 肽类放射性药物针对细菌、真菌与病毒感染研发。
  • 已报道用于病毒显像的新型免疫PET药物,针对HIV持续感染及SARS-CoV2,并有前景看好的抗真菌免疫PET药物hJ5F。

关键数值与推荐

  • 放射性药物研发可快速应对大流行,及时开发出SARS-CoV-2显像剂([64Cu]Cu-NOTA-EK1)。
  • 未来技术可包括适配体与噬菌体应用,乃至设计诊疗一体化感染显像。
  • 另一种可能为将纳米抗体用于免疫PET应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is important to constantly monitor developments in the preclinical imaging arena of infection. Firstly, novel radiopharmaceuticals with the correct characteristics must be identified to funnel into the clinic. Secondly, it must be evaluated if enough innovative research is being done and adequate resources are geared towards the development of radiopharmaceuticals that could feed into the Nuclear Medicine Clinic in the near future. It is proposed that the ideal infection imaging agent will involve PET combined with CT but more ideally MRI. The radiopharmaceuticals currently presented in preclinical literature have a wide selection of vectors and targets. Ionic formulations of PET-radionuclides such 64CuCl2 and 68GaCl2 are evaluated for bacterial infection imaging. Many small molecule based radiopharmaceuticals are being investigated with the most prominent targets being cell wall synthesis, maltodextrin transport (such as [18F]F-maltotriose), siderophores (bacterial and fungal infections), the folate synthesis pathway (such as [18F]F-PABA) and protein synthesis (radiolabelled puromycin). Mycobacterial specific antibiotics, antifungals and antiviral agents are also under investigation as infection imaging agents. Peptide based radiopharmaceuticals are developed for bacterial, fungal and viral infections. The radiopharmaceutical development could even react quickly enough on a pandemic to develop a SARS-CoV-2 imaging agent in a timely fashion ([64Cu]Cu-NOTA-EK1). New immuno-PET agents for the imaging of viruses have recently been published, specifically for HIV persistence but also for SARS-CoV2. A very promising antifungal immuno-PET agent (hJ5F) is also considered. Future technologies could include the application of aptamers and bacteriophages and even going as far as the design of theranostic infection. Another possibility would be the application of nanobodies for immuno-PET applications. Standardization and optimization of the preclinical evaluation of radiopharmaceuticals could enhance clinical translation and reduce time spent in pursuing less than optimal candidates.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kleynhans J, Sathekge MM, Ebenhan T, et al. Preclinical Research Highlighting Contemporary Targeting Mechanisms of Radiolabelled Compounds for PET Based Infection Imaging. Semin Nucl Med. 2023. PMID: 37012169. doi:10.1053/j.semnuclmed.2023.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。